Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple score could spot deadly infection in cirrhosis patients

NCT ID NCT07024355

Knowledge-focused Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study will test a new scoring system (Mansoura score) to predict a serious bacterial infection called spontaneous bacterial peritonitis in people with liver cirrhosis and fluid buildup in the belly. Researchers will enroll 250 adults to see how well the score identifies who needs early antibiotics. The goal is to start treatment faster and reduce illness and death.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this scoring system could help doctors quickly identify liver cirrhosis patients who need antibiotics for a serious infection, potentially reducing deaths.
What could go wrong
This is an early observational study, not a treatment trial. The scoring system may not be accurate enough in real-world settings, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This prospective study included all adult patients with cirrhosis and ascites admitted to AL-Rajhy Liver Hospital between April 2025 and April 2027

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients aged \>18 years * Diagnosed liver cirrhosis * Presence of ascites * Provided written informed consent Exclusion Criteria: * Use of antibiotics within the previous two weeks * Prophylactic treatment for spontaneous bacterial peritonitis (SBP) prior to admission * Ascites not related to portal hypertension, including: * Peritoneal tuberculosis * Peritoneal carcinomatosis * Congestive heart failure * Renal disease * Pancreatitis * Hemorrhagic ascites * Secondary peritonitis * Presence of infections other than SBP, including: * Pneumonia * Urinary tract infection * Skin and soft tissue infection * Presence of malignancy Hematologic diseases * Use of antiplatelet drugs or non-steroidal anti-inflammatory drugs (NSAIDs) * Receipt of platelet or blood transfusion prior to admission * Diseases associated with elevated mean platelet volume (MPV), including: * Diabetes mellitus * Cardiovascular disease * Hyperthyroidism * Immune thrombocytopenia * Myeloproliferative disorders

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver cirrhosis with ascites are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver infectious peritonitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Spontaneous bacterial peritonitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.